Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL.
Fengmei SongYongxian HuYanlei ZhangMingming ZhangTingting YangWenjun WuSimao HuangHuijun XuAlex H ChangHe HuangGuoqing WeiPublished in: Journal for immunotherapy of cancer (2023)
NCT04532268.